prikaz prve stranice dokumenta Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
  Preuzmi
PDF 1.17 MB
Znanstveni rad - Izvorni znanstveni rad
Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
Medicina, 60 (2024), 11; 1905. https://doi.org/10.3390/medicina60111905
Batinić, Josip; Dreta, Barbara; Rinčić, Goran; Mrdeža, Antonia; Jakobac, Karla Mišura; Krišto, Delfa Radić; Vujčić, Milan; Piršić, Mario; Jonjić, Željko; Periša, Vlatka; Sinčić Petričević, Jasminka; Coha, Božena; Holik, Hrvoje; Valković, Toni; Stanić, Marija; Krečak, Ivan; Stojanović, Ante; Sajfert, Domagoj; Bašić-Kinda, Sandra Više autora...

Citirajte ovaj rad

Batinić, J., Dreta, B., Rinčić, G., Mrdeža, A., Jakobac, K. M., Krišto, D. R. ... Bašić Kinda, S. (2024). Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM). Medicina, 60. (11). doi: 10.3390/medicina60111905

Batinić, Josip, et al. "Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)." Medicina, vol. 60, br. 11, 2024. https://doi.org/10.3390/medicina60111905

Batinić, Josip, Barbara Dreta, Goran Rinčić, Antonia Mrdeža, Karla Mišura Jakobac, Delfa Radić Krišto, Milan Vujčić, et al. "Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)." Medicina 60, br. 11 (2024). https://doi.org/10.3390/medicina60111905

Batinić, J., et al. (2024) 'Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)', Medicina, 60(11). doi: 10.3390/medicina60111905

Batinić J, Dreta B, Rinčić G, Mrdeža A, Jakobac KM, Krišto DR, i sur.. Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM). Medicina [Internet]. 20.11.2024. [pristupljeno 02.12.2024.];60(11). doi: 10.3390/medicina60111905

J. Batinić, et al., "Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)", Medicina, vol. 60, br. 11, Studeni 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:534883. [Citirano: 02.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:534883
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
AutorJosip Batinić
AutorBarbara Dreta
AutorGoran Rinčić
AutorAntonia Mrdeža
AutorKarla Mišura Jakobac
AutorDelfa Radić Krišto
AutorMilan Vujčić
AutorMario Piršić
AutorŽeljko Jonjić
AutorVlatka Periša
AutorJasminka Sinčić Petričević
AutorBožena Coha
AutorHrvoje Holik
AutorToni Valković
AutorMarija Stanić
AutorIvan Krečak
AutorAnte Stojanović
AutorDomagoj Sajfert
AutorSandra Bašić-Kinda
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background and Objectives: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). Materials and Methods: This study evaluates the real-world effectiveness and safety of IRd in Croatian RRMM patients. A retrospective analysis was conducted on 164 RRMM patients treated with ixazomib at nine Croatian haematology centres from November 2016 to February 2023. Data on patient demographics, treatment regimens, and outcomes were collected and analysed using Kaplan–Meier survival curves and Cox proportional hazards models in R. The median age at ixazomib initiation was 66 years (range 40–91). Results: The overall response rate (ORR) was 65.8%, with 42% of patients achieving a very good partial response (VGPR) or better. The median progression-free survival (PFS) was 15.4 months, while median overall survival (OS) was 28.2 months. Hematologic toxicities included anaemia (53%), neutropenia (50%), and thrombocytopenia (45%). Infective complications, primarily COVID-19 and pneumonia, were reported in 38% of patients. The safety profile was consistent with previous studies, indicating manageable adverse events. Ixazomib-based therapy is effective and well tolerated in a real-world Croatian RRMM population. Conclusions: The findings align with clinical trial results, demonstrating the applicability of ixazomib in routine clinical practice. Further studies are needed to optimise treatment sequencing and improve patient outcomes.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMedicina
Brojčani podacivol. 60, br. 11, 1905
e-ISSN1648-9144
DOIhttps://doi.org/10.3390/medicina60111905
URN:NBNurn:nbn:hr:184:534883
Datum objave publikacije2024-11-20
URL dokumentahttps://www.mdpi.com/1648-9144/60/11/1905
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-11-27 13:12:18